Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • MJFF Research Grant, 2010
    Patient-specific iPS cell-derived Neurons and Disease-associated LRRK2 Mutations for Parkinson's Disease Research

    Objective/Rationale
    Several underlying genetic risk factors are now established for Parkinson’s disease (PD). Mutations in LRRK2 are the most common genetic cause of the selective neurodegeneration...

  • Therapeutics Development Initiative, 2010
    Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease

    Objective/Rationale
    Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons. No endogenous Nurr1 ligands have been identified, and...

  • MJFF Research Grant, 2010
    Validation of Enzymatic Activity and Neuropathology in G2019S LRRK2-induced Dopaminergic Neurodegeneration in a Pre-clinical Model of Parkinson's Disease

    Objective/Rationale: 
    Mutations in the LRRK2 gene are a common cause of familial and sporadic Parkinson’s disease. Familial LRRK2 mutations induce neuronal toxicity in vitro. Reliable pre-clinical...

  • MJFF Research Grant, 2010
    Generation and Characterization of iPS Neurons from PINK1- and Parkin-linked Parkinson's Disease

    Objective/Rationale: 
    Recent reports have demonstrated that skin cells from patients with Parkinson’s disease can be reprogrammed into pluripotent stem cells (iPS) and subsequently differentiated into...

  • MJFF Research Grant, 2010
    Generation and Characterization of iPS Neurons from PINK1- and Parkin-linked Parkinson's Disease

    Objective/Rationale: 
    Recent reports have demonstrated that skin cells from patients with Parkinson’s disease can be reprogrammed into pluripotent stem cells (iPS) and subsequently differentiated into...

  • MJFF Research Grant, 2010
    Support for your Collaboration on Proof-of-concept clinical trial on the use of the 5-HT1A/1B Partial Agonist Eltoprazine for Treatment of L-DOPA-induced Dyskinesias. - Linked to Bjorklund CIA 2009

    Objective/Rationale:
    We have identified a new potential drug target for Parkinson's disease -- receptors located on the so-called serotonin neurons in the brain -- for alleviation of involuntary...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.